Treatment of Severe COVID-19 Pneumonia With Allogeneic Mesenchymal Stem Cells

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 1, 2020

Primary Completion Date

October 28, 2021

Study Completion Date

October 28, 2021

Conditions
COVID-19 Pneumonia
Interventions
BIOLOGICAL

Mesenchymal Stem Cells (MSCs)

Intravenous injection of 1 million MSCs (MSV cells)/Kg suspended in 100 ml physiological saline solution.

OTHER

Placebo

Intravenous injection of 100 ml physiological saline solution containing no cells

Trial Locations (1)

47012

Hospital Universitario Rio Hortega, Valladolid

All Listed Sponsors
collaborator

Citospin

INDUSTRY

collaborator

University of Valladolid

OTHER

collaborator

Castilla-León Health Service

OTHER

collaborator

Hospital del Rio Hortega

OTHER

collaborator

Instituto de Salud Carlos III

OTHER_GOV

lead

Red de Terapia Celular

INDUSTRY

NCT04361942 - Treatment of Severe COVID-19 Pneumonia With Allogeneic Mesenchymal Stem Cells | Biotech Hunter | Biotech Hunter